0.4752
Schlusskurs vom Vortag:
$0.389
Offen:
$0.3745
24-Stunden-Volumen:
6.17M
Relative Volume:
15.13
Marktkapitalisierung:
$8.74M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.26M
KGV:
-0.4022
EPS:
-1.1814
Netto-Cashflow:
$-13.50M
1W Leistung:
+49.58%
1M Leistung:
-20.85%
6M Leistung:
-83.76%
1J Leistung:
-90.38%
Intensity Therapeutics Inc Stock (INTS) Company Profile
Firmenname
Intensity Therapeutics Inc
Sektor
Branche
Telefon
203-221-7381
Adresse
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Vergleichen Sie INTS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
INTS
Intensity Therapeutics Inc
|
0.4752 | 5.85M | 0 | -16.26M | -13.50M | -1.1814 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten
Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting - PR Newswire
Intratumoral Cancer Treatment Market 2034: EMA, PDMA, FDA - openPR.com
Intensity Therapeutics to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy - marketscreener.com
Breast Cancer Breakthrough: Award-Winning Author Christine Handy Joins Forces With Novel Cancer Drug Developer - Stock Titan
Liposarcoma Clinical Trial Analysis: Key Insights into Rich - GlobeNewswire
Imunon Stock Price, Quotes and Forecasts | NASDAQ:IMNN - Benzinga
Intensity Therapeutics stock hits 52-week low at $0.29 By Investing.com - Investing.com Nigeria
Intensity Therapeutics stock hits 52-week low at $0.29 - Investing.com
Alliance Global Partners Adjusts Price Target for Intensity Therapeutics (INTS) | INTS Stock News - GuruFocus
Benchmark maintains Speculative Buy on Intensity Therapeutics stock - Investing.com
Benchmark maintains Speculative Buy on Intensity Therapeutics stock By Investing.com - Investing.com India
Intensity Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma - openPR.com
Soft Tissue Sarcoma Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Intra-tumoral Cancer Therapies Market to Show Tremendous Growth at a CAGR of 31.3% During the Study Period (2020-2034) | DelveInsight - Yahoo Finance
Intensity stock rating cut to Hold by Brookline Capital - Investing.com Nigeria
Intensity Therapeutics (INTS) Downgraded as Funding Concerns Ari - GuruFocus
Brookline Capital Downgrades Intensity Therapeutics to Hold From Buy - marketscreener.com
Intensity Therapeutics (INTS) Downgraded as Funding Concerns Arise | INTS Stock News - GuruFocus
Intensity Therapeutics downgraded to Hold from Buy at Brookline - TipRanks
Intensity Therapeutics Reports Q1 2025 Financial Results - TipRanks
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Me - Quantisnow
INTS Faces Challenges Yet Advances in Key Cancer Programs | INTS Stock News - GuruFocus
Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - Nasdaq
Health Beat: Muscle loss and cognitive function - WFMZ.com
International Hummus Day arrives with a surge in plant-based picks - WFMZ.com
Curious? Healthy Brain Aging Might Depend On It - WFMZ.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Reg - GuruFocus
Intensity Therapeutics (INTS) Expands Cancer Trial to France | I - GuruFocus
Intensity Therapeutics (INTS) Expands Cancer Trial to France | INTS Stock News - GuruFocus
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast - Yahoo Finance
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com
Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Offerings News Live Feed - Stock Titan
Intensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds - Barchart.com
Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com
Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX
Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX
Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX
In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX
Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com
The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister
Intensity Therapeutics plunges on $2.35M public offering - MSN
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com
Intensity Therapeutics sets terms for $2.35 million offering - Investing.com
Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal
Finanzdaten der Intensity Therapeutics Inc-Aktie (INTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):